AngioDynamics, Inc. (ANGO) Shares Bought by Royce & Associates LP
Royce & Associates LP boosted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 15.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 938,148 shares of the medical instruments supplier’s stock after buying an additional 127,836 shares during the period. Royce & Associates LP owned about 2.56% of AngioDynamics worth $15,207,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Peregrine Capital Management LLC purchased a new position in AngioDynamics during the second quarter worth about $12,133,000. Marshall Wace North America L.P. purchased a new position in AngioDynamics during the second quarter worth about $6,727,000. Great Lakes Advisors LLC purchased a new position in AngioDynamics during the second quarter worth about $3,509,000. Bank of Montreal Can raised its position in AngioDynamics by 126.1% in the second quarter. Bank of Montreal Can now owns 262,846 shares of the medical instruments supplier’s stock worth $4,261,000 after buying an additional 146,583 shares during the last quarter. Finally, Bank of America Corp DE raised its position in AngioDynamics by 580.4% in the first quarter. Bank of America Corp DE now owns 166,555 shares of the medical instruments supplier’s stock worth $2,890,000 after buying an additional 142,076 shares during the last quarter. 95.80% of the stock is currently owned by hedge funds and other institutional investors.
AngioDynamics, Inc. (ANGO) opened at 16.69 on Thursday. The firm has a market capitalization of $610.52 million, a price-to-earnings ratio of 121.82 and a beta of 1.15. The company’s 50-day moving average price is $16.36 and its 200-day moving average price is $16.20. AngioDynamics, Inc. has a 12-month low of $14.80 and a 12-month high of $18.18.
AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. The firm had revenue of $86.90 million for the quarter, compared to the consensus estimate of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 EPS. Equities analysts expect that AngioDynamics, Inc. will post $0.67 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “AngioDynamics, Inc. (ANGO) Shares Bought by Royce & Associates LP” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/angiodynamics-inc-ango-shares-bought-by-royce-associates-lp/1533569.html.
ANGO has been the topic of a number of research analyst reports. Barclays PLC lowered their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 19th. Canaccord Genuity reaffirmed a “hold” rating and set a $16.50 target price on shares of AngioDynamics in a report on Wednesday, May 31st. Zacks Investment Research lowered AngioDynamics from a “hold” rating to a “sell” rating in a report on Thursday, July 20th. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Finally, Cantor Fitzgerald lifted their target price on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. AngioDynamics presently has an average rating of “Hold” and a consensus target price of $18.50.
In related news, CEO James C. Clemmer bought 5,000 shares of the business’s stock in a transaction on Friday, July 21st. The shares were purchased at an average cost of $15.79 per share, with a total value of $78,950.00. Following the acquisition, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,368,724.57. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were bought at an average cost of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,355,722.12. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,316 shares of company stock worth $396,806 over the last ninety days. Company insiders own 1.88% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO).
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.